The riboflavin biosynthetic pathway as a novel target for antifungal drugs against species

Jana Nysten,Arne Peetermans,Dries Vaneynde,Liesbeth Demuyser,Patrick Van Dijck

DOI: https://doi.org/10.1101/2024.03.01.582991

2024-03-01

Abstract:In recent decades, there has been an increase in the occurrence of fungal infections, yet the arsenal of drugs available to fight invasive infections remains very limited. The development of new antifungal agents is hindered by the restricted number of molecular targets that can be exploited, given the shared eukaryotic nature of fungi and their hosts which often leads to host toxicity. In this paper, we examine the riboflavin biosynthetic pathway as a potential novel drug target. Riboflavin is an essential nutrient for all living organisms. Its biosynthetic pathway does not exist in humans, who obtain riboflavin through their diet. Our findings demonstrate that all enzymes in the pathway are essential for , and Among these enzymes, Rib1 and Rib3 are the most promising targets. Auxotrophic strains, which mimic a drug targeting the biosynthesis pathway, experience rapid mortality in the absence of supplemented riboflavin. Nevertheless, the cells can still take up external riboflavin when supplemented. We identified Orf19.4337 as the riboflavin importer in and named it Rut1. We found that Rut1 only facilitates growth at external riboflavin concentrations that exceed the physiological concentrations in the human body, making it unlikely that riboflavin uptake to act as a potential resistance mechanism for a drug targeting the biosynthesis pathway. Interestingly, the uptake system in is more effective than in and enabling an auxotrophic strain to outcompete an auxotrophic strain in lower riboflavin concentrations.

Microbiology